Wave of RSV, particularly dangerous for babies, sweeping across U.S.; doctors urge vaccination

A new wave of Respiratory Syncytial Virus (RSV) is sweeping the U.S., driving increased hospitalizations, particularly among infants and seniors, and underscoring a significant public health need. This surge coincides with the recent market entry of novel RSV immunizations, including Pfizer's Abrysvo and GSK's Arexvy (licensed May 2023), and Moderna's mResvia (June 2024), with Pfizer's vaccine also approved for pregnant women. Health officials are actively recommending these new vaccines for high-risk populations, signaling a growing and sustained demand for these pharmaceutical products and establishing a competitive landscape among key players in the respiratory vaccine market.

Analysis

A significant wave of Respiratory Syncytial Virus (RSV) is currently sweeping across the U.S., leading to increased hospitalizations, particularly among infants and older adults. Emergency room visits for infants under 1 due to RSV rose from 0.4% to 1.2% nationwide within a month, with the virus responsible for up to 300 pediatric deaths and 10,000 senior deaths annually. This early-season surge highlights a critical public health challenge and the urgent need for effective preventative measures.

The market for RSV immunizations has seen recent significant product launches, with Pfizer's Abrysvo and GSK's Arexvy licensed in May 2023, and Moderna's mResvia in June 2024. Pfizer's vaccine holds a distinct advantage as the only one approved for pregnant women, alongside its use for older adults, positioning it favorably in a key demographic. Health officials are actively recommending these new, effective vaccines for high-risk populations, indicating robust demand.

Studies have demonstrated the effectiveness of these RSV immunizations, showing significant reductions in hospitalization rates for babies and preventing symptomatic illness in older adults. However, concerns exist regarding the supply of RSV shots for infants and toddlers, suggesting potential bottlenecks or unmet demand. The broader vaccine landscape is also influenced by recent confusing CDC guidance on COVID-19 vaccines, which could impact overall public confidence and uptake of new immunizations.

Key Decisions for Investors

• Investors should monitor the sales trajectory and market penetration of newly launched RSV vaccines from Pfizer (PFE), GSK, and Moderna (MRNA), particularly given the current surge in cases and public health recommendations.
• Evaluate Pfizer's competitive advantage in the RSV vaccine market, specifically its unique approval for pregnant women, which could drive stronger market share compared to peers.
• Assess potential supply chain constraints for infant and toddler RSV immunizations, as reported shortages could impact revenue recognition and market sentiment for manufacturers.
• Consider the broader regulatory and public perception landscape for vaccines, as recent mixed guidance on COVID-19 vaccinations may influence overall uptake of new immunizations.